Bengaluru: India’s drug maker Zydus Cadila said on Thursday it has submitted an emergency use of the Covid-19 vaccine three doses which showed a 66.6% efficacy in a temporary study and could be a second regulator fire if the regulator approved.
Although Coronavirus infection has dropped from a crushing peak in April and hopefully a tense health care facility, experts have warned the third wave, by saying broad vaccination is one of the best pandemic defenses.
Zydus vaccine “will certainly help in increasing the drives of Indian vaccination as a whole because it will be approved by the fifth,” Prashant Khadayate, a pharmaceutical industry analyst at Globaldata said.
Zydus said the results of the efficacy were based on a temporary analysis of the final stages of more than 28,000 national volunteers, including nearly 1,000 subjects in the age group 12 to 18 years.
The drug maker said that it was evaluating a two-dose regimen for shots.
If approved, ZYCOV-D will be the first DNA vaccine in the world, Zydus said, because it utilizes a portion of the genetic code – DNA or RNA – in the SARS-COV-2 virus to stimulate the immune response to the surge protein.
DNA vaccines are different from other approved Covid-19 shots, which are based on new MRNA technology such as those from Pfizer and Moderna, and established technology such as viral vectors, such as AstraZeneca.
Zydus, which aims to produce up to 120 million doses every year, said his research coincides with the peak of the wave of the two Indian infections and stressed its efficacy of new mutants, especially Delta variants.
However, it does not reveal its efficacy of the variants.